Quoin Pharmaceuticals Ltd ADR QNRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if QNRX is a good fit for your portfolio.
News
-
Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results
-
Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET
-
Quoin Pharmaceuticals Announces Pricing of $6.5 Million Public Offering
-
Quoin Pharma Shares Double After FDA Grants Clearance for Teens in QRX003 Trial
-
Quoin Pharmaceuticals Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies
-
Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Netherton Syndrome Combination Product
Trading Information
- Previous Close Price
- $0.72
- Day Range
- $0.69–0.74
- 52-Week Range
- $0.69–12.00
- Bid/Ask
- $0.71 / $0.73
- Market Cap
- $2.62 Mil
- Volume/Avg
- 41,169 / 684,973
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 4
- Website
- https://www.quoinpharma.com
Valuation
|
Metric
|
QNRX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.13 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
QNRX
Financial Strength
|
Metric
|
QNRX
|
|---|---|
Quick Ratio | 2.99 |
Current Ratio | 3.15 |
Interest Coverage | — |
Quick Ratio
QNRX
Profitability
|
Metric
|
QNRX
|
|---|---|
Return on Assets (Normalized) | −52.46% |
Return on Equity (Normalized) | −99.62% |
Return on Invested Capital (Normalized) | −108.20% |
Return on Assets
QNRX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Wlwyzlzdcv | Nlyld | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ltcqkldys | Fpfln | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ccnvwqwq | Mnnmj | $98.1 Bil | |
MRNA
| Moderna Inc | Hmvvvqh | Pdws | $39.1 Bil | |
ARGX
| argenx SE ADR | Npcdcnb | Pmzp | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Gzryxrncd | Nhy | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Kgyqtxzb | Nrnkcl | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Hmlqcdc | Vntclk | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ljyrpqbxzj | Vrjrdm | $12.5 Bil | |
INCY
| Incyte Corp | Yflstbft | Rsvjmh | $11.9 Bil |